News
11h
TipRanks on MSNWhy Pfizer’s (PFE) Oncology Gamble is Finally Paying Off
Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported breakthrough survival data ...
Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...
Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...
With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with ...
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...
13don MSN
1 Reason to Buy Pfizer (PFE) Stock
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...
Dividend stocks are a time-tested way to retire or protect your portfolio if you are already retired. Their yield can give ...
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.
A few weeks back, we discussed that Pfizer’s (NYSE: PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results